La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Lipum Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Ola Sandborgh

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	less than a year
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	3.2yrs

Mises à jour récentes de la gestion

Recent updates

PDG

Ola Sandborgh (58 yo)

less than a year

Titularisation

Mr. Ola Sandborgh serves as CEO at Lipum AB (publ) since November 09, 2023. He has experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and b...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Olle Hernell	Co-Founder & Director	no data	SEK 303.50k	1.61% SEK 4.1m
Gustav Kihlstrom	Independent Chairman of the Board	3.3yrs	pas de données	pas de données
Björn Löwenadler	Member of Scientific Advisory Board	no data	pas de données	pas de données
Carl-Johan Spak	Independent Director	1.3yrs	pas de données	0.017% SEK 42.0k
Anders Fasth	Member of Scientific Advisory Board	no data	pas de données	pas de données
Lennart Lundberg	Member of Scientific Advisory Board	3.2yrs	pas de données	pas de données
Asa Hansdotter	Independent Director	3.3yrs	pas de données	pas de données
Kristian Sandberg	Independent Director	4.5yrs	pas de données	pas de données
Rikard Holmdahl	Member of Scientific Advisory Board	no data	pas de données	pas de données
Solbritt Dahlqvist	Member of Scientific Advisory Board	no data	pas de données	pas de données
Asa Magnusson	Director	less than a year	pas de données	pas de données

3.2yrs

Durée moyenne de l'emploi

69.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de LIPUM sont considérés comme expérimentés (ancienneté moyenne 3.1 ans).

Lipum Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

High number of new directors

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

Lipum Elects Carl-Johan Spak as New Board Member

Recent updates

Lipum AB (Publ) Welcomes Peter Hovstadius as Chief Medical Officer

New major risk - Financial position

High number of new directors

Lipum AB (publ) Completes Multiple Dose Part of the Phase I Clinical Study

Lipum AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 79.714945 million.

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Lipum Recommends Shareholders to Not Accept Mandatory Cash Offer

Forecast to breakeven in 2025

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) has filed a Follow-on Equity Offering.

Lipum AB (publ) Reports Positive Interim Results from Clinical Phase 1 Study Showing that SOL-116 Reduces Plasma BSSL Levels in Healthy Subjects

Lipum AB (Publ) Receives Funding from Vinnova for an Eurostars Application

Lipum AB (publ) Announces Nomination Committee Appointments

Lipum AB (Publ) Appoints Ola Sandborgh as Chief Executive Officer, Effective from December 1, 2023

New major risk - Revenue and earnings growth

Lipum AB (Publ) Appoints Karin Franck-Larsson as CMO

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Lipum Elects Carl-Johan Spak as New Board Member

Chief Executive Officer recently bought kr161k worth of stock

Lipum AB (publ) Announces the Nomination Committee for the 2023 Annual General Meeting

Chief Executive Officer recently bought kr157k worth of stock

Lipum AB (Publ) Has Initiated A Phase 1 Clinical Study with Its Drug Candidate Sol-116

Lipum AB (publ) announced that it has received SEK 38.999963 million in funding from Flerie Invest AB

Lipum AB (publ) Gets Approval to Start Phase 1 Clinical Trial with Drug Candidate Sol-116

Lipum AB (publ) Appoints Helena Bergström as Chief Medical Officer

Lipum Reports Completion of GLP Toxicology- and Safety Program on the Candidate Drug (SOL-116)

Chief Executive Officer recently bought kr195k worth of stock

Lipum AB (Publ) Reports Gmp Production of Sol-116 Successful

Lipum Recruits Fredrik Seijsing as Scientist

Lipum AB (publ) Initiates GMP-Production for Clinical Trials

Lipum Is At the Final Step Before Clinical Phase

PDG

Titularisation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen